Company profile: Satsuma Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
Products and services
- Dry-Powder DHE Formulation: Proprietary dry-powder dihydroergotamine mesylate formulation engineered for nasal delivery in acute migraine treatment and used within the STS101 drug-device combination for self-administration
- Pre-Filled Nasal Delivery Device: Single-use nasal delivery device pre-filled to enable self-administration of STS101’s DHE powder as part of the drug-device combination for acute migraine
- STS101: Clinical-stage drug-device combination for acute migraine, delivering self-administered DHE nasal powder via a pre-filled, single-use nasal delivery device utilizing a proprietary dry-powder formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Satsuma Pharmaceuticals
Blockade Medical
HQ: United States
Website
- Description: Provider of catheter-based therapeutic devices for the treatment of cerebral aneurysms. Founded in 2011, Blockade Medical is a privately held company with a management team totaling 65+ years in the neurovascular field, committed to bringing products to market that are current standards of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blockade Medical company profile →
Supernus Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinson’s disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Supernus Pharmaceuticals company profile →
Vanqua Bio
HQ: United States
Website
- Description: Provider of next-generation medicines for neurodegenerative diseases, including GCase programs to improve lysosomal function for GBA1 Parkinson’s, idiopathic Parkinson’s, and Dementia with Lewy Bodies; a C5aR1 program to reduce complement-mediated inflammation in neurodegenerative and peripheral inflammatory diseases; and VQ-101, a small-molecule GCase activator designed to cross the blood-brain barrier.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanqua Bio company profile →
Levicept
HQ: United Kingdom
Website
- Description: Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Levicept company profile →
Avation
HQ: United States
Website
- Description: Provider of wearable tibial neuromodulation systems for treating urinary incontinence and urgency from overactive bladder, delivered via a garment and integrated with a mobile app for therapy management and personalized energy delivery, including an eDiary to track patient activity and progress toward goals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avation company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Satsuma Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Satsuma Pharmaceuticals
2.2 - Growth funds investing in similar companies to Satsuma Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Satsuma Pharmaceuticals
4.2 - Public trading comparable groups for Satsuma Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →